Overview

Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes

Status:
Terminated
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Cholecalciferol (vitamin D) may help cancer cells become normal cells. Giving arsenic trioxide together with cholecalciferol (vitamin D) may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving arsenic trioxide together with cholecalciferol (vitamin D) works in treating patients with myelodysplastic syndromes.
Phase:
Phase 2
Details
Lead Sponsor:
Comprehensive Cancer Center of Wake Forest University
Wake Forest University Health Sciences
Collaborator:
National Cancer Institute (NCI)
Treatments:
Arsenic Trioxide
Cholecalciferol